|
| Research Interests for David B. Ridley
Research Interests: Health Economics, Industrial Organization, and Strategic Management
David examines business strategies for innovation and differentiation, and how these strategies interact with government policy. Much of David's research concerns the biopharmaceutical industry. To encourage development of more biopharmaceutical treatments for neglected diseases, David, with Henry Grabowski and Jeffrey Moe, proposed a priority review voucher prize. The prize became law in 2007. - Areas of Interest:
- Health Economics
Industrial Organization
Strategic Management
- Recent Publications
(search)
- Ridley, DB; Lasanta, AM; Storer Jones, F; Ridley, SK, European priority review vouchers for neglected disease product development.,
BMJ global health, vol. 9 no. 1
(January, 2024),
pp. e013686, BMJ [doi] [abs]
- Cuddy, E; Lu, YP; Ridley, DB, FDA Global Drug Inspections: Surveillance Of Manufacturing Establishments Remains Well Below Pre-COVID-19 Levels.,
Health affairs (Project Hope), vol. 42 no. 12
(December, 2023),
pp. 1758-1766 [doi] [abs]
- Liebman, E; Lawler, EC; Dunn, A; Ridley, DB, Consequences of a shortage and rationing: Evidence from a pediatric vaccine.,
Journal of health economics, vol. 92
(December, 2023),
pp. 102819, Elsevier BV [doi] [abs]
- Ridley, DB; Ganapathy, P; Kettler, HE, US Tropical Disease Priority Review Vouchers: Lessons In Promoting Drug Development And Access.,
Health affairs (Project Hope), vol. 40 no. 8
(August, 2021),
pp. 1243-1251 [doi] [abs]
- Ridley, DB; Lee, CY, Does medicare reimbursement drive up drug launch prices?,
Review of Economics and Statistics, vol. 102 no. 5
(December, 2020),
pp. 980-993 [doi] [abs]
|
